Evaluation of the Performance of Lumipulse G1200 for Tumor Marker Assays
Laboratory Medicine Online
;
: 131-138, 2012.
Artículo
en Coreano
| WPRIM
| ID: wpr-145038
ABSTRACT
BACKGROUND:
Tumor markers are used for diagnosing cancers and monitoring responses to cancer therapy. In this study, we evaluated the performance of Lumipulse G1200 (Fujirebio, Japan), a fully automated serum analyzer, for immunoassays of tumor markers.METHODS:
We determined the precision and linearity of assays performed using Lumipulse G1200 and the correlation between the results of this and other analyzers used for tumor markers according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). We used 9 tumor markers, namely, carcinoembryonic antigen, alpha-fetoprotein, cancer antigen 125, cancer antigen 15-3 (CA 15-3), cancer antigen 19-9, prostate specific antigen, protein induced by vitamin K absence or antagonist-II, and pepsinogens I and II. Further, we validated reference intervals using 20 serum samples of healthy individuals.RESULTS:
Lumipulse G1200 yielded acceptable precision with total CV0.975 for all markers, except pepsinogen I (0.9569). The reference intervals provided by the manufacturer met the criteria mentioned in the CLSI guideline.CONCLUSIONS:
Assays using Lumipulse G1200 had high precision, clinically acceptable linearity, and good correlation with the established assays. This indicates that Lumipulse G1200 can be potentially used in routine laboratories.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pepsinógenos
/
Vitamina K
/
Inmunoensayo
/
Alfa-Fetoproteínas
/
Antígeno Carcinoembrionario
/
Biomarcadores de Tumor
/
Antígeno Prostático Específico
/
Pepsinógeno A
Tipo de estudio:
Guía de Práctica Clínica
Idioma:
Coreano
Revista:
Laboratory Medicine Online
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS